The ageing population is a global phenomenon. According to the UN’s “World Population Prospects 2019” by 2100, the world’s population is projected to reach approximately 10.9 billion. Moreover, between 2020 and 2100, the number of people ages 80 and older is expected to increase from 146 million to 881 million.
A progressive disorder, Alzheimer’s disease leads to wasting off the brain cells and is one of the most common causes of dementia. First set of symptoms such as a decline in thinking, behavioural and social skills and disruption in the body’s ability to function start to appear between 40 and 65 years of age.
With the progression of age, the disease progresses and deteriorates the functioning of the brain more rapidly. As per the National Center for Chronic Disease Prevention and Health Promotion, In 2014, an estimated 5 million Americans aged 65 years or older had Alzheimer’s disease. This number is projected to nearly triple to 14 million people by 2060. Even then, it the complexity of the disease makes it hard to have any standard cure and thus the Alzheimer’s disease market lacks any FDA approved therapy.
However, Alzheimer’s is at the forefront of biomedical research. Researchers are working to uncover as many aspects of Alzheimer’s disease and other dementias as possible. Some of the most remarkable progress has shed light on how Alzheimer’s affects the brain. The hope is that better understanding will lead to new treatments.
Many potential approaches are currently under investigation worldwide. Researchers hope to develop therapies targeting specific genetic, molecular, and cellular mechanisms so that the actual underlying cause of the disease can be stopped or prevented.
Several companies have started working toward the development of new therapeutic options in the Alzheimer’s disease market. They are developing therapies targeting specific genetic, molecular, and cellular mechanisms so that the actual underlying cause of the disease can be stopped or prevented. Many promising targets like Beta-amyloid, beta-secretase, and others are under investigation for next-generation drug therapies.
Some of the key players in the therapeutic market changing the Alzheimer’s disease market trends at a global level are Neurotrope bioscience, Amarantus Bioscience Holdings, AgeneBio, Novartis, Cortexyme, TauRx Therapeutics, Otsuka Pharmaceutical, AC Immune, Genentech, Alkahest, AZ Therapies, Cerecin, vTv Therapeutics, and others.
The launch of potential emerging therapies, such as Bryostatin-1 (Neurotrope Bioscience), Eltoprazine (Amarantus Bioscience Holdings), AGB101 (AgeneBio), CAD106 and CNP520 (Novartis), COR388 HCL (Cortexyme), TRx0237 (TauRx Therapeutics), brexpiprazole (Otsuka Pharmaceutical), RO7105705 (Genentech/AC Immune), AKST/GRF6019 (Alkahest), ALZT-OP1 (AZ Therapies), Tricaprilin (Cerecin), Azeliragon (vTv Therapeutics), and others are expected to change the treatment landscape in the upcoming years.
Looking at the rich pipeline, extensive research ongoing, it can surely be said that the dynamics of Alzheimer’s disease (AD) market is anticipated to change in the coming years owing, moreover due to to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecasted period of 2019–2028.